Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Typhoid Fever Clinical Trial

Official title:

A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01123941
• Other study ID #: H01_01TP
• Status: Completed
• Phase: Phase 1
• First received: May 13, 2010
• Last updated: December 16, 2013
• Start date: May 2010
• Est. completion date: November 2010

Study information

• Verified date: December 2013
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: November 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Males and females of age =18 to =40 years.

2. Individuals who, after the nature of the study has been explained to them, have given written consent according to local regulatory requirements.

3. Individuals in good health as determined by the outcome of medical history, physical examination, hematological / hematochemical blood tests and urinalysis and clinical judgment of the investigator.

4. If women, a negative pregnancy test and willingness to use birth control measures for the entire study duration

Exclusion Criteria:

1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.

2. Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.

3. Individuals who are not able to understand and to follow all required study procedures for the whole period of the study.

4. Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

5. Individuals with known or suspected HIV infection or HIV related disease, with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days, or were in chemotherapy treatment within the past 6 months.

6. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

7. Individuals with any serious chronic or progressive disease according to judgment of the investigator.

8. Individuals who have any malignancy or lymphoproliferative disorder.

9. Individuals with history of allergy to vaccine components.

10. Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.

11. Individuals who have previously received any vaccines against typhoid fever.

12. Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccine.

13. Individuals who have received blood, blood products and/or plasma derivatives including parenteral immunoglobulin preparations in the past 12 weeks.

14. Individuals with body temperature > 38.0 degrees Celsius within 3 days of intended study immunization.

15. BMI > 35 kg/m2.

16. Individuals with history of substance or alcohol abuse within the past 2 years.

17. Women who are pregnant or breast-feeding or of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study.

18. Females with history of stillbirth, neonatal loss, or previous infant with anomaly.

19. Individuals who have a previously ascertained or suspected disease caused by S. Typhi.

20. Individuals who have had household contact with/and or intimate exposure to an individual with laboratory confirmed S. Typhi.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Typhoid Fever

Intervention

Biological:
• Typherix
1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
• NVGH Vi-CRM197
1 dose of 0.5 mL containing 25 mcg of Vi-CRM

Locations

Country	Name	City	State
Belgium	Center for the Evaluation of Vaccination (CEV)	Antwerp	Wilrijk (Antwerp)

Sponsors (1)

Lead Sponsor	Collaborator
Novartis

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fe — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Reporting Any Post Immunization Reactions	Solicited reactions collected during the 7-day period after vaccination are pain, erythema, induration, chills, malaise, myalgia, headache, arthralgia and fatigue.	During the 7-day period after vaccination	Yes
Primary	Number of Subjects Reporting Adverse Events		During the 28-day period after vaccination	Yes
Primary	Number of Subjects Reporting Serious Adverse Events (SAEs)		During the 6-month period after vaccination	Yes
Secondary	Anti-Vi ELISA Geometric Mean Concentration (GMC)		At 28 days after vaccination	No